The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy

Oncotarget

Volumn 7, Issue 42, 2016, Pages 68638-68649

  Ahn, Sung Min ^a   Ansari, Adnan Ahmad ^b,c   Kim, Jihun ^b,c   Kim, Deokhoon ^c   Chun, Sung Min ^b,c   Kim, Jiyun ^b   Kim, Tae Won ^b   Park, Inja ^b   Yu, Chang Sik ^b   Jang, Se Jin ^b,c  

^a Gachon University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

Early onset colorectal cancer; Hypermutation; Immunotherapy; PD 1 blockade; POLE

Indexed keywords

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COLON POLYPOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE BURDEN; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; MALE; MICROSATELLITE MARKER; ONSET AGE; PATHOLOGY; POLE GENE; SOMATIC HYPERMUTATION; SOMATIC MUTATION; VALIDATION PROCESS; WHOLE EXOME SEQUENCING; AGED; COLORECTAL TUMOR; DNA SEQUENCE; EXOME; GENETICS; GENOMICS; IMMUNOTHERAPY; METABOLISM; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISSENSE MUTATION; PROCEDURES; VERY ELDERLY;

DNA DIRECTED DNA POLYMERASE ALPHA; POLE PROTEIN, HUMAN; POLY ADP RIBOSE BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA POLYMERASE II; EXOME; FEMALE; GENOMICS; HUMANS; IMMUNOTHERAPY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION, MISSENSE; POLY-ADP-RIBOSE BINDING PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 85002393492     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.11862     Document Type: Article

References (37)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN. 2012. Int J Cancer. 2015; 136:E359-E386
2. Ivanovich JL, Read TE, Ciske DJ, Kodner IJ, Whelan AJ. A practical approach to familial and hereditary colorectal cancer. Am J Med. 1999; 107:68-77
3. Young JP, Win AK, Rosty C, Flight I, Roder D, Young GP, Frank O, Suthers GK, Hewett PJ, Ruszkiewicz A, Hauben E, Adelstein B-A, Parry S, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: Report and review: Early-onset colorectal cancer. J Gastroenterol Hepatol. 2015; 30:6-13
4. Stigliano V, Sanchez-Mete L, Martayan A, Anti M. Earlyonset colorectal cancer: A sporadic or inherited disease? World J Gastroenterol. 2014; 20:12420-12430
5. Siegel RL, Jemal A, Ward EM. Increase in incidence of Colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009; 18:1695-1698
6. Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012; 25:1128-1139
7. Berg M, Ågesen TH, Thiis-Evensen E, Merok MA, Teixeira MR, Vatn MH, Nesbakken A, Skotheim RI, Lothe RA. Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Mol Cancer. 2010; 9:100
8. Tanskanen T, Gylfe AE, Katainen R, Taipale M, Renkonen-Sinisalo L, Mecklin J-P, Järvinen H, Tuupanen S, Kilpivaara O, Vahteristo P, Aaltonen LA. Exome sequencing in diagnostic evaluation of colorectal cancer predisposition in young patients. Scand J Gastroenterol. 2013; 48:672-678
9. Valle L, Hernández-Illán E, Bellido F, Aiza G, Castillejo A, Castillejo M-I, Navarro M, Seguí N, Vargas G, Guarinos C, Juarez M, Sanjuán X, Iglesias S, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet. 2014; 23:3506-3512
10. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337
11. Boland CR, Goel A. Microsatellite instability in Colorectal cancer. Gastroenterology. 2010; 138:2073-2087.e3
12. Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, den Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. Hum Mutat. 2011; 32:557-563
13. Ou J, Niessen RC, Vonk J, Westers H, Hofstra RMW, Sijmons RH. A database to support the interpretation of human mismatch repair gene variants. Hum Mutat. 2008; 29:1337-1341
14. Briggs S, Tomlinson I. Germline and somatic polymerase γ and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol. 2013; 230:148-153
15. Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi D-A, Ratner E, Azodi M, et al. Polymerase e (POLE) ultramutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 2015; 138:11-17
16. Gool IC van, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, Bruyn M de, Palles C, Nout RA, Kroon CD de, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IPM, et al. POLE proofreading mutations elicit an antitumor immune response in Endometrial cancer. Clin Cancer Res. 2015; 21:3347-3355
17. Xiao Y, Freeman GJ. The Microsatellite Instable (MSI) Subset of Colorectal Cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015; 5:16-18
18. Pruitt KD, Brown GR, Hiatt SM, Thibaud-Nissen F, Astashyn A, Ermolaeva O, Farrell CM, Hart J, Landrum MJ, McGarvey KM, Murphy MR, O'Leary NA, Pujar S, et al. RefSeq: an update on mammalian reference sequences. Nucleic Acids Res. 2014; 42:D756-D763
19. Palles C, Cazier J-B, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013; 45:136-144
20. Valle L, Hernández-Illán E, Bellido F, Aiza G, Castillejo A, Castillejo M-I, Navarro M, Seguí N, Vargas G, Guarinos C, Juarez M, Sanjuán X, Iglesias S, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet. 2014:ddu058
21. Kane DP, Shcherbakova PV. A common cancer-associated DNA Polymerase e mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res. 2014; 74:1895-1901
22. Church DN, Briggs SEW, Palles C, Domingo E, Kearsey SJ, Grimes JM, Gorman M, Martin L, Howarth KM, Hodgson SV, Kaur K, Taylor J, Tomlinson IPM. DNA polymerase e and d exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013; 22:2820-2828
23. Kunkel TA, Erie DA. Dna Mismatch Repair. Annu Rev Biochem. 2005; 74:681-710
24. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer. 2014; 14:786-800
25. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010; 7:153-162
26. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, Van Loo P, Tarpey PS, Coupland P, Behjati S, Pollett A, Lipman T, Heidari A, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015; 47:257-262
27. Matsuda T, Bebenek K, Masutani C, Hanaoka F, Kunkel TA. Low fidelity DNA synthesis by human DNA polymerase-γ. Nature. 2000; 404:1011-1013
28. Fan G-W, Li C-J, Zhang X. Updates in colorectal cancer stem cell research. J Cancer Res Ther. 2014; 10:233
29. Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrooks M, Clipson L, Albrecht D, Bacher J, Washington MK, Weichert J, Halberg RB. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene. 2014; 33:2245-2254
30. Leystra AA, Deming DA, Zahm CD, Farhoud M, Paul Olson TJ, Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, Sullivan R, Washington MK, Torrealba JR, Weichert JP, et al. Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res. 2012; 72:2931-2936
31. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJP, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012; 488:660-664
32. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372:2509-2520
33. Calis JJA, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Kesmir C, Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013; 9:e1003266
34. Network TCGAR. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497:67-73
35. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25:1754-1760
36. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20:1297-1303
37. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31:213-219